Targeted inhibition of Focal Adhesion Kinase Attenuates Cardiac Fibrosis and Preserves Heart Function in Adverse Cardiac Remodeling

Jie Zhang,Guangpu Fan,Hui Zhao,Zhiwei Wang,Fei Li,Peide Zhang,Jing Zhang,Xu Wang,Wei Wang

DOI: https://doi.org/10.1038/srep43146

IF: 4.6

2017-02-22

Scientific Reports

Abstract:Cardiac fibrosis in post-myocardial infarction (MI), seen in both infarcted and non-infarcted myocardium, is beneficial to the recovery of heart function. But progressively pathological fibrosis impairs ventricular function and leads to poor prognosis. FAK has recently received attention as a potential mediator of fibrosis, our previous study reported that pharmacological inhibition of FAK can attenuate cardiac fibrosis in post MI models. However, the long-term effects on cardiac function and adverse cardiac remodelling were not clearly investigated. In this study, we tried to determine the preliminary mechanisms in regulating CF transformation to myofibroblasts and ECM synthesis relevant to the development of adverse cardiac remolding in vivo and in vitro. Our study provides even more evidence that FAK is directly related to the activation of CF in hypoxia condition in a dose-dependent and time-dependent manner. Pharmacological inhibition of FAK significantly reduces myofibroblast differentiation; our in vivo data demonstrated that a FAK inhibitor significantly decreases fibrotic score, and preserves partial left ventricular function. Both PI3K/AKT signalling and ERK1/2 are necessary for hypoxia-induced CF differentiation and ECM synthesis; this process also involves lysyl oxidase (LOX). These findings suggest that pharmacological inhibition of FAK may become an effective therapeutic strategy against adverse fibrosis.

multidisciplinary sciences

What problem does this paper attempt to address?

The problem that this paper attempts to solve is how cardiac fibrosis affects cardiac function after myocardial infarction (MI), and how to reduce this adverse cardiac remodeling and protect cardiac function by targeted inhibition of Focal Adhesion Kinase (FAK).

Specifically, the paper explores the following points:

1. **The role of FAK in cardiac fibrosis**: Researchers first focused on the activation of FAK during the process of cardiac fibrosis, especially its effect on the activation and phenotypic conversion of cardiac fibroblasts (CFs) under hypoxic conditions. Through in vitro experiments, they found that the activation of FAK is closely related to the transformation of fibroblasts into myofibroblasts induced by hypoxia, and this process is dose - and time - dependent.

2. **The effect of FAK inhibitors**: Next, the researchers used the FAK inhibitor PF - 573228 to observe its effect on cardiac fibrosis. The results showed that pharmacological inhibition of FAK significantly reduced the differentiation of myofibroblasts under hypoxic conditions, reduced the synthesis of extracellular matrix (ECM), thereby reducing the degree of cardiac fibrosis.

3. **The effect of FAK inhibitors on cardiac function**: To evaluate the effect of FAK inhibitors on cardiac function, the researchers conducted experiments in a mouse model of myocardial infarction. The results showed that FAK inhibitors can significantly reduce the degree of cardiac fibrosis after myocardial infarction, while preserving some left ventricular functions, such as left ventricular ejection fraction (LVEF), fractional shortening (FS), and systolic left ventricular volume (LV Vol; s) and other indicators have been improved.

4. **The role of downstream signaling pathways**: In addition, the study also explored how FAK inhibitors exert their effects by influencing the PI3K/AKT and ERK1/2 signaling pathways. These signaling pathways play a key role in hypoxia - induced CFs differentiation and ECM synthesis, and FAK inhibitors can restore the normal functions of these signaling pathways, reduce the expression of LOX (lysyl oxidase), and further reduce fibrosis.

In summary, this paper aims to explore an effective treatment strategy by targeted inhibition of FAK to combat cardiac fibrosis after myocardial infarction and the resulting cardiac dysfunction.